Is EC 700-544-5 Safe in Breastfeeding

I am a breastfeeding mother and i want to know if it is safe to use EC 700-544-5? Is EC 700-544-5 safe for nursing mother and child? Does EC 700-544-5 extracts into breast milk? Does EC 700-544-5 has any long term or short term side effects on infants? Can EC 700-544-5 influence milk supply or can EC 700-544-5 decrease milk supply in lactating mothers?

• DrLact safety Score for EC 700-544-5 is 5 out of 8 which is considered Unsafe as per our analyses.
• A safety Score of 5 indicates that usage of EC 700-544-5 may cause serious side effects in breastfed baby.
• Our study of different scientific research indicates that EC 700-544-5 may cause moderate to high side effects or may affect milk supply in lactating mother.
• Our suggestion is to use safer alternate options rather than using EC 700-544-5 .
• It is recommended to evaluate the advantage of not breastfeeding while using EC 700-544-5 Vs not using EC 700-544-5 And continue breastfeeding.
• While using EC 700-544-5 Its must to monitor child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
• Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.

Inhibitor of BCR-ABL and SRC tyrosine kinase that is used for treatment of Chronic Myeloid Leukemia with positive Philadelphia chromosome. At latest update, relevant published data on excretion into breast milk were not found. Because of high serum protein-binding capacity, excretion into breast milk in significant amount is seemingly unlikely. If continuation of safely breastfeeding is desired without assuming high risk for potentially severe side-effects, elimination of total burden of drug should be kept. For this to happen, it should be wait for 10 half-lives (T ½). It means that 7 days should be waited before resuming breastfeeding. Meanwhile, frequent pump-and-dump is recommended for maintenance of milk production.

Although the amount of EC 700-544-5 in milk appears to be small and one breastfed infants apparently experienced no adverse effects during maternal use of EC 700-544-5, no long-term data are available. Because EC 700-544-5 is 98% bound to plasma proteins, the amounts in milk are likely to be low. However, there is little published experience with EC 700-544-5 during breastfeeding, and an alternate drug may be preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be discontinued during EC 700-544-5 therapy and for 14 days after the last dose.

A woman with chronic myeloid leukemia received EC 700-544-5 (dosage not stated) for 20 months before pregnancy, throughout pregnancy and continuing during 9 months of breastfeeding (extent not stated). No adverse reactions were reported in her breastfed infant.[2]